Dabigatran linked to lower incidence of bleeding events in atrial fibrillation Anticoagulation with dabigatran was associated with fewer bleeding complications compared with warfarin among patients ...

Dabigatran has been associated with an increase in acute coronary events when compared with warfarin in several randomized trials, and now in a meta-analysis by Uchino and Hernandez. We critically ...

Test results presented have implications for patients if they require emergency surgery. Last month, the FDA approved idarucizumab (marketed as Praxbind) as an agent that specifically reverses the ...

In two trials exploring potential new indications, dabigatran (Pradaxa; Boehringer Ingelheim) failed to show significant advantages over standard treatments for embolic stroke of undetermined source ...

Learn everything you need to know about Dabigatran-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Ascend Laboratories has recalled 10 lots of Dabigatran Etexilate capsules, used to lower the risk of blood clots and strokes, after finding the nitrosamine in the drug was above the FDA’s acceptable ...

MONTREAL, QC – Sex differences exist in effectiveness, dose use, and safety for the novel oral anticoagulant (NOAC) dabigatran (Pradaxa, Boehringer Ingelheim) for patients with atrial fibrillation (AF ...

Dabigatran etexilate (dabigatran) is a novel, oral, reversible, direct thrombin inhibitor that exhibits several advantages over warfarin for therapeutic anticoagulation. The predictable ...

Ascend Laboratories LLC. has recently issued a nationwide recall of Dabigatran Etexilate Capsules. USP 75 mg and 150 mg over concerns about the presence of nitrosamine (N-Nitroso-Dabigatran). It is ...

Ascend Laboratories, maker of generic dabigatran etexilate, is recalling 10 manufacturing lots of the oral anticoagulant because of an unacceptably high level of a possible carcinogen, according to a ...

The availability of dabigatran 110 mg in the US may be a favorable therapeutic option for patients at high risk of bleeding, who may be willing to accept a higher probability of stroke for a reduced ...

Use of the novel oral anticoagulants dabigatran and rivaroxaban is contraindicated in patients undergoing dialysis because the drugs can bioaccumulate and cause increased bleeding. Dabigatran and ...